Epidemiological Insights on Medication Concurrency and Polypharmacy in People With Multiple Sclerosis in Greece

Author:

Bakirtzis Christos1ORCID,Nikolaidis Ioannis1,Boziki Marina-Kleopatra1,Grigoriadou Eleni1,Karakasi Maria-Valeria2,Moysiadis Theodoros3,Kesidou Evangelia1,Papazisis Georgios4,Grigoriadis Nikolaos1

Affiliation:

1. From the Multiple Sclerosis Center, 2nd Department of Neurology (CB, IN, M-KB, EG, EK, NG), Aristotle University of Thessaloniki, Thessaloniki, Greece

2. C' Department of Psychiatry (M-VK), Aristotle University of Thessaloniki, Thessaloniki, Greece

3. The Department of Computer Science, School of Sciences and Engineering, University of Nicosia, Nicosia, Cyprus (TM)

4. Department of Clinical Pharmacology (GP), Aristotle University of Thessaloniki, Thessaloniki, Greece

Abstract

ABSTRACT BACKGROUND Besides disease-modifying therapies, various pharmacologic agents are frequently prescribed to people with multiple sclerosis (MS) for symptom treatment and for comorbid conditions. The present study aims to investigate the types and frequencies of agents prescribed to people with MS in Greece using records from the nationwide digital prescription database. METHODS Prescription records for 21,218 people (65.9% women) with MS were included in the study. The criterion for study inclusion was a minimum of 3 months of continuous prescription of an agent. Identified treatments were further examined by age group. RESULTS Antispasticity agents (17.5%) and fampridine (14.5%) were the most regularly prescribed symptomatic medications. Antihypertensives (21.1%) and drugs for affective disorders, including antidepressants (36.1%) and anxiolytics (16.2%), were the most frequently prescribed medications for comorbid conditions. Antidepressants were prescribed at almost equally high rates among individuals older than 40 years. Hypertension was one of the leading comorbidities among the study sample, with rates rising significantly after age 40 years and plateauing after age 60 years. Polypharmacy was observed in 22.5% of the study sample, with a higher incidence among people with MS older than 60 years (46.98%). CONCLUSIONS Agents prescribed for the treatment of disease symptoms and other medical conditions are expected to positively affect quality of life in people with MS. However, polypharmacy seems to be particularly high, especially in the aged population. The potential implications of polypharmacy in the disease course should further be explored.

Publisher

Consortium of Multiple Sclerosis Centers

Subject

Advanced and Specialized Nursing,Neurology (clinical)

Reference33 articles.

1. Association between multiple sclerosis disease severity and adherence to disease-modifying therapies;Burkhard;J Manag Care Spec Pharm.,2021

2. Comorbidity in multiple sclerosis;Magyari;Front Neurol.,2020

3. Occulomotor neural integrator dysfunction in multiple sclerosis: insights from neuroimaging;Bede;Front Neurol.,2018

4. Polypharmacy in multiple sclerosis: current knowledge and future directions;Thelen;Mo Med.,2021

5. Comorbidity in multiple sclerosis: implications for patient care;Marrie;Nat Rev Neurol.,2017

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3